A Study of BMS-986340 Alone or in Combination with Nivolumab for Patients with Advanced Kidney Cancer
Background: Nivolumab (Opdivo®) is a Health Canada-approved immunotherapy for the treatment of kidney cancer and works by targeting a molecule called PD-1. Blocking the PD-1 molecule helps prime the body’s immune defences to more effectively target and destroy cancer cells; these therapies are often called immune...
A Study of GSK4381562 Alone or in Combination with Dostarlimab or GSK4428859A for Patients with Advanced Kidney Cancer
Background: GSK4381562, Dostarlimab, and GSK4428859A belong to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Dostarlimab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab...
A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of INCB 99280 in Combination with Ipilimumab for Patients with Advanced Kidney Cancer
Background: Ipilimumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Ipilimumab targets the immune checkpoint molecule CTLA-4 and allows the body to increase the...
A Study of KFA115 Alone or in Combination with Tislelizumab in Patients with Advanced Kidney Cancer
Background: Tislelizumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Tislelizumab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab (Opdivo®), which is...
A Study of 23ME-00610 in Patients with Advanced Kidney Cancer
Background: 23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®),...
A Study of Different Immune and Targeted Therapies for 2nd Line (or higher) Treatment of Kidney Cancer (Substudy 03B)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor...
A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer
Background: Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®). Pembrolizumab (Keytruda®) is an immunotherapy drug that is...
A Study of Belzutifan + Pembrolizumab versus Pembrolizumab Alone for Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. Belzutifan (Welireg®) is a drug that is...
A Study of Combination Durvalamab + Savolitinib versus Sunitinib or Durvalamab Alone in Patients with Papillary Kidney Cancer
Background: Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a...
A Study of Different Immune and Targeted Therapies for 1st Line Treatment of Kidney Cancer (Substudy 03A)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI)...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...
A Study of OC-001 Alone or in Combination with a PD-L1 Inhibitor in Patients With Advanced Solid Tumours
Background: OC-001 is an experimental immunotherapy drug that works by targeting a molecule called TNF. This type of treatment works by preventing inflammation in the body and enhancing the anti-cancer effect of certain other treatments. Since this drug is still in the clinical trial phase, it has...
A Study of BMS-986315 Alone or in Combination with Nivolumab/Cetuximab in Patients with Advanced Solid Tumours
Background: BMS-986315 is an experimental immunotherapy drug that works targetting a molecule called NKG2A. This may allow the body to mount a more robust anti-cancer immune response. This drug will be tested alone, as well as in combination with one of two Health Canada-approved anti-cancer therapies: Nivolumab...
A Study of RO7284755 Alone or in Combination With Atezolizumab in Patients with Advanced Solid Tumours
Background: RO7284755 is an experimental drug belonging to a new class of immunotherapies called "fusion proteins". This means that the researchers have "fused" together two drugs to produce a single compound capable of targeting two different molecules with a single medication. This fusion protein works by...
A Study on Preventing Toxicity in Kidney Cancer Patients Using Fecal Transplantation (PERFORM)
Background: The term "microbiome" refers to all of the microorganisms (including bacteria, fungi, and other living things) that live inside and on the surface of the human body. There is growing evidence that suggests the microbiome plays a large role in our overall health and wellbeing....
Stereotactic Body Radiation Therapy (SBRT) with Ipilimumab and Nivolumab for Advanced Kidney Cancer (CYTOSHRINK)
Background: Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues. The drugs used in...
A Study of HERV-E Targeted T Cell Therapy in Patients with Advanced Kidney Cancer
Background: A T cell is a type of white blood cell. It plays an important role in the immune system by attacking virus-infected cells, foreign cells (such as bacteria), and cancer cells. However, we know that some T cells are much more effective at certain tasks...
A Study for Patients with Advanced Kidney Cancer who are Currently on Treatment or in Follow-up for a Pembrolizumab Study (KEYNOTE-587)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. The purpose of this study is to assess...